Dose emission and aerodynamic characterization of the terbutaline sulphate dose emitted from a Turbuhaler at low inhalation flow

Pharmaceutical Development and Technology

Volumn 18, Issue 4, 2013, Pages 944-949

  Abdelrahim, M E ^a,b   Assi, K H ^b   Chrystyn, H ^c  

^a Beni Suef University   (Egypt)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

^c UNIVERSITY OF HUDDERSFIELD   (United Kingdom)

Author keywords

Aerodynamic characters; Inhalation flow rate; Terbutaline; Total emitted dose; Turbuhaler

Indexed keywords

TERBUTALINE SULFATE;

ARTICLE; DRUG DELIVERY SYSTEM; FLOW RATE; IN VITRO STUDY; PARTICLE SIZE; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AEROSOLS; DRY POWDER INHALERS; PARTICLE SIZE; TERBUTALINE; TIME FACTORS;

EID: 84877859184     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2011.620970     Document Type: Article

References (27)

1. Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates. Respir Med 2003;97:181-187.
2. Tarsin W, Assi KH, Chrystyn H. In-vitro intra- and inter-inhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler. J Aerosol Med 2004;17:25-32.
3. Weda M, Zanen P, de Boer AH, Barends DM, Frijlink HW. An investigation into the predictive value of cascade impactor results for side effects of inhaled salbutamol. Int J Pharm 2004;287:79-87.
4. Newman SP, Moren F, Trofast E, Talaee N, Clarke SW. Terbutaline sulphate Turbuhaler: effect of inhaled flow rate on drug deposition and efficacy. Int J Pharm. 1991;74(2-3):209-13.
5. Borgström L, Derom E, Ståhl E, Wåhlin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996;153:1636-1640.
6. Ross DL, Schultz RK. Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products. J Aerosol Med 1996;9:215-226.
7. Assi KH, Chrystyn H. The different resistance of dry powder inhalers (DPIs). Am J Respir Crit Care Med 2001;163:A443.
8. Hawksworth GM, James L, Chrystyn H. Characterization of the inspiratory manoeuvre when asthmatics inhale through a Turbohaler pre- and post-counselling in a community pharmacy. Respir Med 2000;94:501-504.
9. Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990;65:308-310.
10. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A et al.; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456.
11. British Pharmacopoeia. Preparations for inhalation. Aerodynamic assessment of fine particles-fine particle dose and particle size distribution (Ph. Eur. method 2.9.18). In: Stationery Office, editor. British Pharmacopoeia. London 2005. p. A277-90.
12. United States Pharmacopeia. Aerosols, nasal sprays, metered dose inhalers and dry powder inhalers. The United States pharmacopeia 28 [and] The national formulary 23: The board of trustees; 2005. p. 2359-2377.
13. European Pharmacopeia. 2.9.18.: Preparations for inhalation: aerodynamic assessment of fine particles.: Strasbourg, France; 2002. p. 209-217.
14. Nadarassan DK, Assi KH, Chrystyn H. Aerodynamic characteristics of a dry powder inhaler at low inhalation flows using a mixing inlet with an Andersen Cascade Impactor. Eur J Pharm Sci 2010;39:348-354.
15. Van Oort M. In vitro testing of dry powder inhalers. Aerosol Sci Technol 1995;22:364-73.
16. Palander A, Mattila T, Karhu M, Muttonen E. In vitro comparison of three salbutamol-containing multidose dry powder inhalers: Buventol Easyhaler®, Inspiryl Turbuhaler® and Ventoline Diskus®. Clin Drug Investig 2000;20:25-33.
17. Brown PH, Ning AC, Greening AP, McLean A, Crompton GK. Peak inspiratory flow through Turbuhaler in acute asthma. Eur Respir J 1995;8:1940-1941.
18. van der Palen J. Peak inspiratory flow through diskus and turbuhaler, measured by means of a peak inspiratory flow meter (In-Check DIAL). Respir Med 2003;97:285-289.
19. Broeders ME, Molema J, Hop WC, Folgering HT. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction. J Aerosol Med 2003;16:131-141.
20. Tarsin W, Corrado OJ, Brownlee K, et al. Inter-individual variability of peak inhalation rate through different inhalers by asthmatic children and adults and those with COPD. Eur Respir J 2001;18:P900 (133S
21. Abdelrahim ME. Emitted dose and lung deposition of inhaled terbutaline from Turbuhaler at different conditions. Respir Med 2010;104:682-689.
22. Borgström L, Bondesson E, Morén F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J 1994;7:69-73.
23. Hill LS, Slater AL. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir Med 1998;92:105-110.
24. Prime D, Grant AC, Slater AL, Woodhouse RN. A critical comparison of the dose delivery characteristics of four alternative inhalation devices delivering salbutamol: pressurized metered dose inhaler, Diskus inhaler, Diskhaler inhaler, and Turbuhaler inhaler. J Aerosol Med 1999;12:75-84.
25. Meakin BJ, Cainey JM, Woodcock PM. Simulated 'in-use' and 'mis-use' aspects of the delivery of terbutaline sulphate from Bricanyl TurbohalerTM dry powder inhalers. Int J Pharm. 1995;119:103-8(2)
26. Meakin BJ, Cainey JM, Woodcock PM. Drug delivery characteristics of Bricanyl TurbohalerTM dry powder inhalers. Int J Pharm. 1995;119:91-102(1)
27. Hillery AM, Lloyd AW, Swarbrick J. Pulmonary drug delivery. Drug delivery and targeting for pharmacists and pharmaceutical scientists. London: Taylor & Francis; 2001. p. 269-300.